PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA
Clinical trials for PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to outsmart Chemo-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…
Matched conditions: PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New hope for recurrent ovarian cancer: drug combo and surgery may extend life
Disease control OngoingThis study looked at adding the drug bevacizumab to standard chemotherapy (carboplatin and paclitaxel or gemcitabine) and surgery for people with ovarian, peritoneal, or fallopian tube cancer that came back after initial treatment. Over 1,000 participants were randomly assigned t…
Matched conditions: PRIMARY PERITONEAL TRANSITIONAL CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC